This swing-trade for Conatus Pharmaceuticals, (Nasdaq:
Another indicator I see that is quite appealing is from Stochastic Oscillator. As you will see in the chart, Stochastic Oscillator has been on the money with
Resistance Levels & Potential Exits
Near-term I am looking for CNAT to close above: 1.96 -> 2.07 -> 2.16 -> 2.20 -> 2.55.
A move past $2.55 could bring CNAT into the high $2 or low $3 range.
Furthermore, I feel long term investors have a good opportunity to open or add to positions. Technical Analysis traders tend to gravitate toward “nice charts”; bringing additional volume to the table. Statistically, after 3 passes at a resistance level resistance strength dwindles dramatically which could send CNAT soaring to the referenced range.
MS Money Moves feels CNAT is undervalued and that the sell-off after disappointing top-line ENCORE-PH results was an overreaction. But, with that comes opportunity.
There are two binary events that we are bullish on in 2019; and a third where our position is neutral.
- Top-line results from ENCORE-NF (NASH Fibrosis)
- Expected in the 1st half of 2019
- We predict
CNATwill hit their primary endpoint: Improve fibrosis by at least one stage from baseline without worsening of NASH compared to the placebo as determined by liver biopsy.
- ENCORE-PH (Portal Hypertension) extension results
- Expected in mid-2019
- We predict improved clinical outcomes will be observed compared to the placebo. MELD, Child-Pugh scores, and biomarker data (presumably ALT, AST, cCK18, and caspase-3/7) should indicate improved liver function.
- Top-line results from ENCORE-LF (Liver Function)
- Expected in mid-2019
- In this clinical trial,
emricasanis up against the worst NASH has to offer: Decompensated Cirrhosis.
- Luckily, the primary endpoint is improving event-free survival compared to a placebo rather than a change in Hepatic Venous Pressure Gradient (HVPG).
- With over 2-years of dosing, we believe the probability of meeting the primary endpoint is greater than 50%.
If we are correct, then top-line results from ENCORE-NF should be a massive upward catalyst. In lieu of any unexpected developments CNAT’s valuation should appreciate into the data readout. The other binary events discussed could sustain the positive price action.
I am/we are long CNAT.
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.